Foresite Capital Management II’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-146,800
| Closed | -$2.77M | – | 7 |
|
|
2019
Q3 | $2.77M | Sell |
146,800
-1,439,420
| -91% | -$16.5M | 0.59% | 7 |
|
|
2019
Q2 | $18.7M | Hold |
1,586,220
| – | – | 10.5% | 5 |
|
|
2019
Q1 | $21.7M | Hold |
1,586,220
| – | – | 9.78% | 4 |
|
|
2018
Q4 | $16.3M | Hold |
1,586,220
| – | – | 8.62% | 3 |
|
|
2018
Q3 | $26.4M | Sell |
1,586,220
-100,000
| -6% | -$1.81M | 9.77% | 3 |
|
|
2018
Q2 | $26.6M | Hold |
1,686,220
| – | – | 9.39% | 3 |
|
|
2018
Q1 | $21.4M | Buy |
1,686,220
+642,388
| +62% | +$9.29M | 7.12% | 5 |
|
|
2017
Q4 | $12M | Hold |
1,043,832
| – | – | 4.18% | 5 |
|
|
2017
Q3 | $12.8M | Hold |
1,043,832
| – | – | 5.18% | 4 |
|
|
2017
Q2 | $12M | Buy |
1,043,832
+87,791
| +9% | +$1.62M | 5.48% | 4 |
|
|
2017
Q1 | $19.9M | Sell |
956,041
-39,355
| -4% | -$871K | 8.53% | 4 |
|
|
2016
Q4 | $20.7M | Buy |
995,396
+192,672
| +24% | +$5.01M | 10.39% | 3 |
|
|
2016
Q3 | $26.3M | Buy |
802,724
+201,795
| +34% | +$6.15M | 12.56% | 3 |
|
|
2016
Q2 | $15M | Buy |
600,929
+70,513
| +13% | +$1.91M | 10.26% | 4 |
|
|
2016
Q1 | $13M | Buy |
530,416
+110,419
| +26% | +$2.56M | 6.36% | 7 |
|
|
2015
Q4 | $13.9M | Buy |
419,997
+75,227
| +22% | +$2.54M | 4.65% | 8 |
|
|
2015
Q3 | $11.3M | Hold |
344,770
| – | – | 3.43% | 9 |
|
|
2015
Q2 | $18.3M | Buy |
344,770
+187,639
| +119% | +$6.82M | 6.41% | 7 |
|
|
2015
Q1 | $4.54M | Sell |
157,131
-87,869
| -36% | -$2.41M | 2.69% | 12 |
|
|
2014
Q4 | $7.13M | Buy |
+245,000
| New | +$4.4M | 4.88% | 5 |
|
Foresite Capital Management II's ALDR Position: Q4 2019 in Review
Foresite Capital Management II sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 146,800 shares — an estimated $2.77M sold.
Foresite Capital Management II first reported a position in ALDR in Q4 2014 and held it in 20 quarters. The position peaked at $26.6M in Q2 2018. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- Foresite Capital Management II reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Foresite Capital Management II sold 146,800 Alder Biopharmaceuticals shares in Q4 2019, an estimated $2.77M.
- Foresite Capital Management II first reported a position in Alder Biopharmaceuticals in Q4 2014 and held it in 20 quarters.
- Foresite Capital Management II's Alder Biopharmaceuticals position peaked at $26.6M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on Foresite Capital Management II's 13F filing for Q4 2019, filed 5 Feb 2020.